Volatile ride for Ocugen Inc stock price on Wednesday moving between $8.32 and $9.32

S&P TSX Capped Composite...

US Dollar vs CAD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

Volatile ride for Ocugen Inc stock price on Wednesday moving between $8.32 and $9.32

The Ocugen Inc stock price gained 1.32% on the last trading day (Wednesday, 13th Oct 2021), rising f... View Full Article on StockInvest.us

Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Apr 2024 to May 2024

Click Here for more Ocugen Charts.

Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From May 2023 to May 2024

Click Here for more Ocugen Charts.

Ocugen Inc News

Ocugen to Host Conference Call on Tuesday, May 14 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2024 Financial Results
Friday 3 May 2024 (1 day ago) • GlobeNewswire Inc.

Ocugen Announces CSO to Present on Modifier Gene Therapy at Retina World Congress
Thursday 2 May 2024 (2 days ago) • GlobeNewswire Inc.

Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024
Monday 29 April 2024 (5 days ago) • GlobeNewswire Inc.

UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting
Friday 26 April 2024 (1 week ago) • GlobeNewswire Inc.

Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting
Friday 26 April 2024 (1 week ago) • GlobeNewswire Inc.

Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy
Friday 19 April 2024 (2 weeks ago) • GlobeNewswire Inc.

Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets
Friday 12 April 2024 (3 weeks ago) • GlobeNewswire Inc.

Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
Wednesday 10 April 2024 (3 weeks ago) • GlobeNewswire Inc.

Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication
Monday 8 April 2024 (4 weeks ago) • GlobeNewswire Inc.

Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic Atrophy
Friday 5 April 2024 (4 weeks ago) • GlobeNewswire Inc.

Ocugen Provides Business Update with Certain Financials for the Year Ending 2023
Tuesday 2 April 2024 (1 month ago) • GlobeNewswire Inc.

Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST—a Modifier Gene Therapy—in GARDian Study for Stargardt Disease
Monday 1 April 2024 (1 month ago) • GlobeNewswire Inc.

More Ocugen Inc News Articles

Code Green Apparel (PK)

1812 Brewing (PK)

Moon Equity (PK)

Bell Buckle (PK)

Anavex Life Sciences

Digital Brand Media and ... (PK)

Good Vibrations Shoes (PK)

AMC Entertainment

Rennova Health (PK)

Hannover House (PK)

Intergrated Cannabis Sol... (PK)

Voip Pal Com (QB)

Trump Media and Technology

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions